BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

GlucoTec, Inc. Completes Series A Preferred Stock Financing


9/19/2011 8:13:54 AM

GREENVILLE, S.C., Sept. 19, 2011 /PRNewswire/ -- GlucoTec, Inc., the privately-held parent company of Glytec, LLC, today announced that it has completed a Series A Preferred Stock financing totaling $8,273,078. Glytec will use the capital primarily to expand its direct US sales force, increase its international presence and advance research and development.

"We also look forward to welcoming...some very experienced and knowledgeable healthcare expertise onto our Board, which will enhance the breadth and vision of the Company...," said Dr. Robert E. Fischell, Chairman of GlucoTec, Inc. "Glytec continues to provide innovative guidance systems for the effective management of metabolic conditions, principally glycemia," said Dr. Fischell. "The health and safety of patients...is paramount... ."

Glytec, LLC has developed and deployed network-based systems for glycemic management under the trade name of G+™ Enterprise Edition since 2010.

The financing was led by Sea Dragon Healthcare Partners, L.P., with participation by Standard Pacific Capital Holdings LLLP. M.M. Dillon & Co. LLC acted as placement agent, and Honigman Miller Schwartz and Cohn LLP served as legal advisor.

About GlucoTec, Inc. and Glytec, LLC

Headquartered in Greenville, SC, Glytec offers real-time glycemic management systems for individualized dosage recommendations of insulin, glucose and saline, considering all pertinent patient information such as demographics, lab results, and risk factors. The systems can be installed locally or operated remotely across the Internet. The Company's glycemic management experience includes over a million proven patient hours using Glytec's systems. Research over many years has yielded products and systems that monitor patient progress in real time and provide alerts when patients may be adversely impacted.

For more information visit www.glucotec.com.

About M.M. Dillon & Co.

Dillon & Co. is an employee-owned partnership where industry and product specialists provide creative, idea-driven advice and solutions to its institutional and corporate clients. M.M. Dillon offers public and private financing, M&A advisory and restructuring advisory services.

Forward-Looking Statements

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward looking statement.

www.glucotec.com

Contact:

Trefor Thomas

CEO and President

864-429-6700

665 North Academy Street,

Greenville, South Carolina 29601


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->